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SH2 domain containing inositol-5-phosphatase (SHIP1) is an important modulator of innate
and adaptive immunity. In mice, loss of SHIP1 provokes severe ileitis resembling Crohn’s
disease (CD), as a result of deregulated immune responses, altered cytokine production
and intestinal fibrosis. Recently, SHIP1 activity was shown to be correlated to the presence
of a CD-associated single nucleotide polymorphism in ATG16L1. Here, we studied SHIP1
activity and expression in an adult cohort of CD patients.
Methods
SHIP1 activity, protein and mRNA expression in peripheral blood mononuclear cells from
CD patients in clinical remission were determined by Malachite green assay, Western blot-
ting and qRT-PCR respectively. Genomic DNA was genotyped for ATG16L1 rs2241880.
Results
SHIP1 protein levels are profoundly diminished in a subset of patients; however, SHIP1
activity and expression are not correlated to ATG16L1 SNP status in this adult cohort.
Conclusions
Aberrant SHIP1 activity can contribute to disease in a subset of adult CD patients, and war-
rants further investigation.
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Introduction
The SH2 domain-containing inositol-5’-phosphatase 1 (SHIP1), predominantly expressed in
hematopoietic tissues [1], is required for the regulation of immune cell compartments, lym-
phoid and innate immune cell function and intestinal fibrosis [2,3].We and others have shown
that SHIP1-/- mice spontaneously develop an intestinal inflammatory phenotype resembling
the inflammatory bowel syndrome (IBD) Crohn’s disease (CD), with increased granulocyte
infiltration and a profound T cell depletion observed in the small intestine [4,5]. Development
of a CD-like phenotype in SHIP1-/- mice is dependent on hematopoietic cells, as transplanta-
tion of SHIP1-/- hematolymphoid cells into wild type mice is sufficient to transfer ileitis and
WT bone marrow transplantation cures SHIP1-/- mice of mucosal inflammatory disease in
both the lungs and small intestine [4,6]. Furthermore, while elective SHIP1 deficiency in the
myeloid compartment alone is not sufficient to cause CD or pneumonia in SHIP1-/- mice [7],
dual lineage deletion of SHIP1 in both the T- and myeloid cell compartments causes CD-like
disease [4]. The role of SHIP1 in human disease is as yet unclear. While enhanced SHIP1
mRNA expression was observed in biopsies from CD patients [8], Ngoh and colleagues re-
cently demonstrated decreased SHIP1 protein expression and activity in peripheral blood
mononuclear cells (PBMCs) and biopsies in a cohort consisting mainly of treatment-naive
subjects with ileal CD [9,10]. Interestingly, this downregulation was correlated with the pres-
ence of a single nucleotide polymorphism (SNP) in the ATG16L1 gene, one of the best de-
scribed CD risk genes, which lies adjacent to the SHIP1 gene, INPP5D. Furthermore, SHIP1
activity was inversely correlated to the expression of IL1b, which contributes to disease sever-
ity. Genetic contribution to disease as well as disease behavior differs between cohorts [11]. In
addition, treatments may affect SHIP1 activity and expression. We therefore analysed SHIP1
activity and expression in a daily practice cross-sectional cohort of adult patients in the Neth-
erlands, to determine to what extent aberrant SHIP1 activity may contribute to CD pathology
in these patients. Our data indicate that SHIP1 expression is abrogated in a small subset of CD
patients and SHIP1 activity in general is decreased, but SHIP1 activity and expression are not
correlated to ATG16L1 status in this adult cohort of patients.
Material and methods
Patients
Heparin-anticoagulated blood was obtained from each subject using standard venipuncture
technique, at the Erasmus University Medical Center, according to institutional guidelines
(METC-2004-168). In total, 34 patients were included for SHIP1 activity assays (Table 1).
Diagnosis of CD was established based on standard criteria, by clinical assessment, radiology,
endoscopy and histology. Patients who were in clinical remission according to Harvey Brad-
shaw criteria, had low CRP levels, or did not receive intensification of treatment at the time of
blood collection were eligible for inclusion. There were no other exclusion criteria. See S1
Table for individual patient characteristics.
Phosphatase assay
For every experiment with CD patients, healthy donors were included in parallel as normal
controls. Phosphatase assays were performed as earlier described [12]. PBMCs were isolated
from Heparin-anticoagulated blood by Ficoll (Amersham, Upsala, Sweden) density centrifuga-
tion and lysed in IP-lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton X100, 1 mM PMSF, Halt protease inhibitor). Alternatively, OPM2, U266, MDA-MB-
231 or MCF7 cells were washed with PBS, and lysed in IP-lysis buffer. Protein content was
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determined by RC/DC protein assay as per manufacturer’s directions (Bio-Rad Laboratories,
Hercules CA). SHIP1 or OCRL-1 were immunoprecipitated from 200 μg protein using SHIP1
(P1C1) or OCRL (4E3) antibodies from Santa Cruz Biotechnology (Santa Cruz, CA) and Gam-
mabind sepharose (GE healthcare, Diegem, Belgium). Beads were washed twice with IP lysis
buffer and once with TBS/MgCl2 (10mM) and resuspended in TBS/MgCl2. Immunoprecipi-
tated SHIP1 was incubated in the presence of 100μM PtdIns(3,4,5)P3 (Echelon Biosciences,
Salt Lake City,UT) for 35 minutes, whereas immunoprecipitated OCRL1 was incubated with
PtdIns(4,5)P2. Malachite Green solution was added according to manufacturer’s instructions,
and the plate was read after 20 minutes. Background (OD640 of gammabind sepharose beads
control) was subtracted from obtained OD640 values of immunoprecipitates to present the
total cellular SHIP1 activity (per 200 μg protein). Human recombinant SHIP2 (0.025 μg/μl)
was used as positive control for the Malachite Green reaction. As the amount of activity
observed is dependent on the total input of SHIP1 protein into the immunoprecipitation, the
intrinsic SHIP1 activity was determined by correcting the SHIP1 activity levels for SHIP1
expression levels in the lysate, as determined by quantitative Western blot analysis.
Quantitative Western blot analysis
Immunoblotting of PBMC lysates was performed as earlier described, with some adjustments
[13]. After preparation of lysates for immunoprecipitation, an aliquot of this same lysate was
taken for Western blot analysis. Gels were blotted on Immobilon-FL transfer membrane
(Millipore, Billerica, MA). Anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies
were used according to manufacturer’s directions, and blots were scanned by Odyssey infrared
imaging (LI-COR Biosciences, Lincoln, NE). SHIP1 P1C1 and β-actin antibodies were from
Table 1. Patient characteristics (patients included in the SHIP activity assay).
Number, n 34
Mean age, yr (range) 37 (18–61)
Sex, n (%)
- female 18 (53%)
- male 16 (47%)
Mean age at diagnosis, yr (range) 25 (10–55)
Mean duration of disease, yr (range) 12 (1–32)
Location, n (%)
- terminal ileum (L1) 9 (26.5%)
- colon (L2) 10 (29.4%)
- ileocolon (L3) 15 (44.1%)
Disease behaviour
- B1 15 (44.1%)
- B2 11 (32.4%)
- B3 8 (23.5%)
Resection, n (%) 16 (47%)
CRP (mg/L, mean±SEM) 3.4±1.09
Medication, n (%)
- None 9 (26.5%)
- 5-ASA 5 (14.7%)
- Steroids 3 (8.8%)
- immunosuppressives 11 (32.3%)
- Anti-TNF 16 (47.1%)
https://doi.org/10.1371/journal.pone.0182308.t001
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Santa Cruz Biotechnology, Santa Cruz, CA. SHIP2 and PTEN antibodies were from Cell Sig-
naling Technology (Beverly, MA). Quantification was performed using Odyssey 3.0 software.
To calculate the relative SHIP1, phospho-SHIP1, SHIP2 or PTEN levels, densitometric values
of these phosphatases were divided by densitometric values of the β-actin signal in the same
lanes.
Cells and cell lines
PBMCs from concentrated lymphocyte fractions (Sanquin Bloodbank, Amsterdam, the Neth-
erlands) were isolated by Ficoll density centrifugation and resuspended in PBS/0.5% bovine
serum albumin (BSA)/2mM EDTA. Enrichment of T cells, B cells and monocytes was per-
formed by magnetic activated cell sorting (MACS) through CD3 positive selection, CD19
positive selection and CD14 positive selection, respectively (Miltenyi Biotec, Auburn, CA),
according to manufacturer’s protocol.
Multiple Myeloma (MM) cell lines RPMI8226, U266 and OPM2 (ATCC, Rockville, MD)
were routinely maintained in Iscove’s Modified Dulbecco’s Medium (IMDM, ATCC, Rock-
ville, MD) supplemented with 10% fetal calf serum (FCS, Mediatech, Manassas, VA), whereas
MCF-7 and MDA-MB-231 breast cancer cells were cultured in Eagle’s Minimal Essential
Medium (EMEM) with 10% FCS, L-glutamine and 0.1 mg/ml insulin.
Immunohistochemistry
Cytocentrifuge preparations of isolated PBMCs or Caco2 cells (6x105) were fixed in ice-cold
acetone, and incubated overnight with SHIP1 antibody in PBS containing 5% goat serum and
0.05% Tween20 at 4˚C. Slides were washed with PBS/0/05%Tween20 and incubated with
horseradish peroxidase conjugated antibodies (Dako, Heverlee, Belgium). Peroxidase activity
was demonstrated using 0.05M Tris-HCl buffer containing 0.5 mg/ml 3,3’-diaminobenzidine
tetrahydrochloride (DAB, Sigma, St Louis, MO) and 0.03% H2O2. Slides were counterstained
with haematoxylin, mounted in Kaiser glycerol and evaluated using light microscopy (Leica,
Solms, Germany).
FACS analysis
After erythrocyte lysis of whole blood, white blood cells were resuspended in PBS containing
1% Fetal Calf Serum (FCS, Sigma, St Louis, MO) and 2.5 mM EDTA. Cells were stained with
CD3-AmCyan, CD19-phycoerythrin (PE) (all from BD Bioscience, Sharon, MA), CD14-
PerCP-CY5.5 (Biolegend, San Diego, CA), washed, and fluorescence intensities were measured
by FACS analysis (BD FacsCanto-II). Viable cells were gated based on FSC/SSC plots (P1),
CD3+, CD19+ and CD14+ cells were represented as a percentage of P1.
Genomic DNA isolation and SNP analysis
For ATG16L1 SNP status, genomic DNA was isolated from erythrocyte-lysed whole blood
using the Wizard Genomic DNA purification Kit from Promega (Madison, WI) as per manu-
facturers’ instructions and rs2241880 status was determined by KBioscience UK ltd, Hertfor-
shire, UK, using fluorescence based competitive allele-specific PCR.
qRT-PCR from total RNA
RNA was extracted from whole blood and 300ng was reverse-transcribed with the QuantiTect
Reverse Transcription Kit (Qiagen) following manufacturers recommendations. Resulting cDNA
was diluted 3-fold, and used in triplicate qRT-PCR for amplification of two housekeeping genes
SHIP1 expression in IBD
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(RPLP1 forward primer: AGCCTC ATC TGCAAT GTA GGG, reverse primer: TCA GACTCC TCG
GATTCT TCT TT and PPIA forward primer: ATGGTC AAA CCCACC GTG T, reverse primer
TCTGCT GTC TTT GGGACC TTG TC) and INPP5D (forward primer: AAG TGTCGT CTC TCC
ACCC, reverse primer: CGG GGA TTCTCG TTT GAAAAA GG), using 2xSYBR green Master Mix
(Roche Applied Sciences) on a Roche LightCycler480. Melting curve analysis was performed to
confirm the identity of amplified products and assays were performed in duplicate. The 2nd deriv-
ative max for each amplification was used to calculate relative expression of SHIP1 according to
the ΔΔCt method between healthy control and IBD patients. Notably, ΔCt computations were
made using RPLP rather than PPIA based on its greater abundance (lower Ct values) and reduced
variability (lower standard deviations).
Statistical analysis
Differences in protein expression and activity levels between healthy controls and CD patients
were tested by non-parametric test for unpaired samples (Mann Whitney test) using GraphPad
Prism 5 software (La Jolla, CA). Three group comparisons of median variation were performed
by Kruskal-Wallis non-parametric testing.
Ethical considerations. This study was approved by the ethical board of the Erasmus MC,
Rotterdam, The Netherlands (protocol MEC-2004-168). Patients in clinical remission and
healthy controls were included after written informed consent was obtained.
Results
Abrogated SHIP1 activity and protein expression in a subset of CD
patients
We set out to investigate SHIP1 expression and activity in isolated peripheral blood mononu-
clear cells (PBMCs) from a cohort of adult CD patients (mean age 37yr [18–61]), 53% female,
see Table 1) and healthy controls (mean age 32 yr [24–56], 25% female). As PBMC isolates
are a heterogeneous population consisting mainly of lymphocytes (T-cells and B-cells) and
monocytes, altered composition of these cell subsets or differences in SHIP1 expression in
these subsets could potentially affect total PBMC SHIP1 expression and activity. We first
showed that there are minor differences in SHIP1 expression between different cell subsets (S1
Fig, panel A). However, as there were no significant differences between CD patients (n = 15)
and healthy controls (n = 10) in the percentage of CD19+ B-cells, CD3+ T-cells or CD14+
monocytes, this is unlikely to affect results (See S1 Fig, panel B).
SHIP1 enzymatic activity was determined by precipitating endogenous SHIP1 from cells
and incubating precipitates with the SHIP1 substrate PtdIns(3,4,5)P3. The specificity and selec-
tivity of this approach was shown by comparing phosphatase activity in SHIP1-deficient and
proficient cell lines (Fig 1A–1C), and the quantitative range of this assay in peripheral blood
mononuclear cells (PBMCs) was determined (S1 Fig, panel C). SHIP1 activity was subse-
quently determined in PBMCs from CD patients (n = 34) and healthy controls (n = 25). No
significant difference in total cellular SHIP1 activity was observed between patients and con-
trols (0.15±0.01 vs 0.18±0.02 AU p = 0.175). However, the SHIP1 activity measured in cells is
of course dependent on the amount of SHIP1 protein present in the cell lysates. Interestingly,
SHIP1 protein levels were at or below detection level in 5 patients (14.7%) (examples shown in
Fig 2A lower panel). No obvious clinical differences were noted between these and other CD
patients (#5, 6, 8, 13 and 28, see S1 Table). As expected, total cellular SHIP1 activity was abro-
gated in patients in whom SHIP1 protein expression was lost (Fig 2A upper panel). In the
remainder of patients, SHIP1 protein was detected and even increased (5.8±0.6 vs 3.8±0.5,
SHIP1 expression in IBD
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p = 0.0084, see examples in S2 Fig, panel A), implicating that intrinsic enzymatic activity of the
SHIP1 protein is reduced as compared to healthy controls (SHIP1 activity/SHIP1 expression
1.14±0.2 for CD vs 2.40±0.6 for HC, p = 0.0006, Fig 2B). In line with the increased protein
expression, we also observed an enhanced mRNA expression in PBMCs from CD patients com-
pared to healthy controls (Fig 2C). MRNA was available of 3 of the 5 patients with abrogated
SHIP1 expression, and was not absent in these patients, suggesting that a post translational
mechanism accounts for the impaired SHIP1 expression in these patients. No differences in
protein expression levels of the inositol phosphatases SHIP2 and PTEN were observed (see Fig
2D and 2E, examples in Fig 2A and S2 Fig, panel B).
SHIP1 activity and expression are not related to ATG16L1 polymorphism
The INPP5D gene encoding SHIP1 lies adjacent to the CD-risk gene ATG16L1. Large genome
wide association studies have shown the SNPs rs2241880 in ATG16L1 to be strongly associated
with CD development[14]. Ngoh et al found a correlation between ATG16L1 SNP status and
SHIP1 activity and expression in their cohort[9]. We therefor stratified our adult CD patients
and healthy controls for whom genomic DNA was available (total n = 48) by the number of
ATG16L1 risk alleles. The number of risk alleles carried by the donor did not affect either
SHIP1 activity (Fig 3A) or mRNA expression (Fig 3B).
Discussion
Genetic ablation of SHIP1 causes a Crohn’s-like phenotype in mice [4,5], and it was recently
demonstrated that SHIP1 protein expression and activity is decreased in PMBCs and biopsies
from CD patients, which was linked to the presence of the ATG16L1 risk allele rs2441880
[9,10]. It has been suggested that rs12994997, a SNP in close linkage disequilibrium with
rs2441880, could be an expression quantitative trait locus for INPP5D [15]. In the current
Fig 1. Specific SHIP1 activity measurement. (A) Specificity of the assay was determined by immunoprecipitation (IP) of SHIP1 from multiple myeloma cell
lines (U266 and OPM2) that express SHIP1 (see Western blot insert of whole cell lysates) and breast cancer cell line (MCF7) that does not. Phosphatase
activity of immunoprecipitates was determined by adding the SHIP1 substrate PtdIns(3,4,5)P3, followed by Malachite Green reaction. Human recombinant
SHIP2 was used as positive control for the phosphatase assay. Only immunoprecipitates from SHIP1-competent cells show phosphatase activity. (B)
OCRL1, SHIP2 or SHIP1 were immunoprecipitated from SHIP1-competent U266 cells and SHIP1-negative MDA-MB-231 (MDA) breast cancer cells. IPs
were run on Western blot and probed for SHIP1, SHIP2 and OCRL1 (upper panel). Whole cell lysates (WCL) were also subjected to Western blot analysis of
these phosphatases (lower panels). OCRL1 and SHIP2 were precipitated from both MDA-MB-231 and OPM2 cells, whereas SHIP1 was only observed in
OPM2, emphasizing specificity of the IP. (C) Malachite Green phosphatase assay (wells shown in lower panels) shows no activity in SHIP1 precipitates from
MDA-MB-231 cells, whereas SHIP1 activity was observed in U266 cells. In contrast, OCRL1 phosphatase activity was detected in both cell lines.
https://doi.org/10.1371/journal.pone.0182308.g001
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manuscript, we demonstrate that while in the majority of adult CD patients intrinsic SHIP1
activity is decreased, this is unaffected by the number of ATG16L1 risk alleles. In addition, an
increase rather than a decrease in SHIP1 mRNA and protein expression was observed, which
corrects total cellular levels of SHIP1 activity. Interestingly, Arijs et al. recently also reported
increased mRNA expression of SHIP1 in mucosal biopsies from CD patients, although phos-
phatase activity was not reported[8]. Differences between our study and that of Ngoh et al.
may be explained by the different cohorts studied (age, treatment, disease location) or different
SHIP phosphatase assays used.
It is becoming apparent that several individual triggers need to combine for IBD to become
manifest, and that not all patients suffer from the same molecular defects contributing to their
disease. Thus, SHIP1 deficiency is also not expected to contribute to disease in all patients. It is
therefore of interest that our study demonstrates that SHIP1 protein expression is abrogated in
only a subset of CD patients, resulting in greatly decreased total cellular SHIP1 activity and
potentially contributing to disease pathology in this subset of CD patients. Expression of
Fig 2. Aberrant SHIP1 activity and expression in adult CD patients. (A) PBMCs from CD patients and healthy controls (HC) were lysed, phosphatase
assay performed. Examples of 3 of 5 CD patients with abrogated SHIP1 expression are shown. Lower panels show SHIP1, PTEN and actin protein in the
same PBMC lysates of CD patients and healthy controls. Phosphatase activity in these patients was tested in duplicate, with identical results. (B) Correction
of SHIP1 phosphatase activity for the amount of SHIP1 protein in the lysates shows that intrinsic SHIP1 enzymatic activity is significantly lower in CD patients
compared to HC. (C) Increased mRNA and protein (examples in S2A Fig) expression compensates for the reduced intrinsic enzymatic activity (CD patients
[n = 47] vs healthy controls [n = 42], 1.68 fold increase, p = 0.0042). RNA was available of three of the five SHIP1-deficient patients (open circles). (C) PTEN
protein expression in PBMC lysates from CD patients and healthy controls (HC) were determined by Western blot analysis, and corrected for Actin levels in
the same samples. Quantification of individual experiments, including mean ±SD are shown. (D,E) PTEN (D) and SHIP2 (E) protein expression in PBMC
lysates from CD patients and healthy controls (HC) were determined by Western blot analysis, and corrected for Actin levels in the same samples.
Quantification of individual experiments, including mean ±SD are shown (examples in Fig 2A lower panel and S2B Fig).
https://doi.org/10.1371/journal.pone.0182308.g002
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SHIP1 mRNA was not abrogated in these patients, implying that a translational or post-trans-
lational mechanism contributes to the decrease in SHIP1 protein levels in this subset of
patients.
The molecular mechanisms contributing to the dichotomy in SHIP1 expression remain
unclear. Large genome wide association studies have now identified over 140 genetic loci asso-
ciated with the development of CD. However, as yet only 10% of total disease variance has
been explained [15], and rare variants not previously identified by GWAS are now being rec-
ognized [16]. The ATG16L1 variant rs2241880 lies in a region (IBD10, 2q37 locus) that also
contains other SNPs that co-segregate with disease, and it is possible that genes other than
ATG16L1 at this locus may contribute to pathogenesis of CD. This notion is not unprece-
dented, as a similar phenomenon is observed at chromosome 1 (IBD risk locus 7), where sev-
eral genes within this 1p36 locus confer risk of CD (genes encoding Runx3, Casp9, p110δ). In
addition, modulation of SHIP1 mRNA by miR155 or protein by ubiquitibation and proteaso-
mal degradation could provide two other potential mechanisms for posttranslational modifica-
tion of the SHIP1 protein [12,17].
In toto, our study shows that SHIP1 activity in PBMCs is decreased in adult CD patients
either through reduced intrinsic enxymatic activity or reduced protein expression, and we pro-
pose that in addition to ATG16L1, SHIP1 may contribute to the risk conferred by the 2q37 CD
risk locus.
Supporting information
S1 Table. Clinical details of individual patients for whom SHIP1 activity was measured.
(DOC)
S1 Fig. SHIP1 activity measurement is affected by amount of SHIP1 protein present in the
lysate, but does not depend on PBMC cell distribution. (A) The main components of
PBMCs constitute T-cells, B-cells and monocytes and these subsets were isolated from PBMCs
by positive selection with CD3-, CD19- and CD14-microbeads respectively, followed by man-
ual MACS sorting. Isolated fractions were lysed, proteins separated by Western blot analysis
Fig 3. SHIP1 expression and activity are independent of ATG16L1 SNP status. ATG16L1 rs2241880 SNP status was determined for those subjects for
whom genomic DNA was available. Groups were stratified according to protective (AA), heterozygous (AG) or risk (GG) alleles. (A) SHIP1 activity corrected
for total amount of SHIP1 present in the lysates is shown. The number of risk alleles does not affect SHIP1 intrinsic activity levels. (B) SHIP1 mRNA levels
corrected for RPLP1 mRNA levels are shown for patients and controls, stratified according to ATG16L1 SNP status. The number of ATG16L1 risk alleles
does not affect SHIP1 mRNA expression.
https://doi.org/10.1371/journal.pone.0182308.g003
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and immunoblotted for SHIP1 protein. Equal loading was confirmed by reprobing blots with
antibodies against Actin. Lower panel: cytospots were made from whole PBMC fraction and
stained with SHIP1 antibodies, showing no differences between different cell types. Specificity
of the antibody was confirmed by negative staining of cytospots of Caco2 cells. (B) Differences
in PBMC subsets could potentially affect the amount of SHIP1 protein measured. However.
no differences in the percentages of CD19+ B-cells, CD3+ T-cells or CD14+ monocytes were
observed between CD patients (n = 15 and healthy controls (HC, n = 10) by FACS analysis of
PBMCs (mean ±SEM). (C) OPM2 cells were lysed, and dilutions with increasing amounts of
total protein were subjected to SHIP1 phosphatase assay. Dilutions were also subjected to
Western blot analysis, and total SHIP1 levels quantified by Odyssey 3 software. SHIP1 activity
and SHIP1 expression patterns show excellent correlation, demonstrating that the amount of
SHIP1 protein input determines SHIP1 activity measured.
(TIF)
S2 Fig. Examples of SHIP1 activity and SHIP1, SHIP2 and PTEN expression in CD
patients and healthy controls. (A) Representative Western blot examples of patients (CD)
and healthy controls (HC) showing increased SHIP1 expression, which did not correspond
with SHIP1 activity levels. (B) Representative Western blot examples showing no difference in
PTEN or SHIP2 expression between CD patients and healthy controls (HC).
(TIF)
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